PRAX - Praxis Precision Medicines to Participate in TD Cowen's 44th Annual Health Care Conference

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the TD Cowen 44 ^th Annual Health Care Conference, taking place in Boston from March 4 – 6, 2024. In addition to conducting one-on-one investor meetings, management will participate in a corporate panel discussion.

This live webcast will also be available through the Events & Presentations page of the Investors + Media section of the company’s website www.praxismedicines.com . A replay of the webcast will be available on Praxis’ website for 90 days following the event.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook , LinkedIn and Twitter/X .

Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452  Media Contact:Dan FerryLife Science AdvisorsDaniel@lifesciadvisors.com617-430-7576